Pfizer, Novartis, Amgen, Eli Lilly and J&J lead pharma lobbying spend amid policy changes. Issues include 340B program, drug ...

As­traZeneca CEO Pas­cal So­ri­ot called on Eu­rope to step up in­vest­ments and “pro­tect its health sov­er­eign­ty” as it ...

Representatives from large vaccine makers say they are committed to their pipelines, despite a new wave of scrutiny in the US ...

China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains ...

Ascletis Pharma's obesity drug ASC30 shows puzzling results in Phase 1b trial, with high dose less effective than lower doses ...

The FDA has asked Novavax to commit to producing post-marketing data of its Covid vaccine, the clearest example yet that the ...

Zealand Pharma hires Eli Lilly veteran Utpal Singh as CSO to advance peptide platform, following Roche obesity drug deal and ...

Telenutrition platform Nourish has raised $70 million and reached profitability a little more than a year after its last ...

A Bay Area protein design startup wants to build more potent antibody-drug conjugates, and is starting with $20 million in ...

Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

Repertoire Immune Medicines makes a major announcement in April. And this year is no different. The Flagship ...

A small Northwestern University spinout attempting to develop a twist on biologics has pulled together a $30 million Series A ...